NextFin News - China's initial public offering market is accelerating back toward the frenetic pace of 2023, but the revival is cracking at the edges. Mainland A-share listings surged 37% in number and 85% in proceeds through the first half of 2026, and Hong Kong's IPO pipeline nearly doubled. Yet the deals that actually reach the tape tell a different story: the year's largest Hong Kong debut closed below its offer price, China's first U.S. listing of 2026 plunged 46.8% in a single session, and roughly half of Hong Kong's 179 listings since January 2025 now trade lower than they did three months earlier. The question is no longer whether China's IPO machine can be switched back on. It is whether investors will keep paying for what it produces.
The Revival by the Numbers
The arithmetic of the rebound is striking. Through the end of June, around 70 companies listed on mainland China's three exchanges — Shanghai, Shenzhen and Beijing — raising RMB 69.3 billion, up from 51 IPOs and RMB 37.3 billion in the same period a year earlier. Shanghai alone accounted for RMB 30.5 billion from 19 deals; Shenzhen added RMB 27.5 billion from 16. The Beijing Stock Exchange, the venue for smaller innovators, recorded the largest number of new listings. The first quarter set the tone: 29 companies raised a combined 25.7 billion yuan in the three months through March, a 56% increase in proceeds from the same period in 2025.
That recovery follows one of the sharpest contractions in the market's modern history. In 2023, China's A-share market hosted 313 new listings that raised RMB 356.3 billion — a pace regulators later judged unsustainable. In 2024, the tap was turned off: just 101 IPOs raised RMB 68 billion, a 68% drop in volume and an 81% drop in proceeds. The slowdown was deliberate. The China Securities Regulatory Commission, under chairman Wu Qing, explicitly adopted "counter-cyclical adjustment" of IPO supply to protect a secondary market that had lost roughly 40% from its 2021 peak. Analysts at the time framed the logic plainly: a slower pace of IPOs frees up the funds tied up in new-share subscriptions and returns them to the secondary market, while scarcity of new listings supports the performance of stocks already trading.
What changed in 2026 was policy direction. The CSRC sped up approvals and reintroduced rules allowing qualified pre-revenue technology companies to raise money — a direct channeling of household and institutional savings toward Beijing's technological self-reliance agenda, which was elevated in the 15th Five-Year Plan. "The regulator made it clear on many occasions that high-quality tech companies would be welcome to go public," said Wang Zhengzhi, an analyst at Guotai Haitong Securities. "Therefore, the pace of IPOs is expected to speed up further in 2026." Wang estimates full-year proceeds could reach about RMB 150 billion, with between 90 and 150 companies listing. That would bring the market within striking distance of 2023's peak without ever fully closing the gap — a recovery shaped more by policy imperative than by investor demand.
Where the Cracks Are Showing
The strain is most visible in post-listing performance, where the gap between what issuers want and what buyers will pay keeps widening.
On July 9, Luxshare Precision, the consumer-electronics assembler whose founder Wang Laichun is China's richest woman, made one of Hong Kong's biggest debuts of 2026, raising HK$24.3 billion. The H-shares opened below the HK$63.28 issue price, touched an intraday loss approaching 10%, and closed the session down 1.55% at HK$62.30. Days later the shares were still trading about 0.4% underwater. The problem was pricing discipline: the H-share offer was set at only about a 13% discount to the company's A-shares, far narrower than the 20% to 30% discount that comparable cross-listed issuers typically offer to entice Hong Kong investors. Nearly half the offering — more than HK$11 billion — was locked up by 26 cornerstone investors including Temasek, GIC and the Abu Dhabi Investment Authority, leaving a thin free float and no cushion when selling pressure arrived. The fundamentals did not help: almost 80% of Luxshare's revenue comes from consumer electronics, with Apple alone contributing more than half of sales.
A week earlier, on June 26, DSC Holdings — known domestically as Dasouche, a provider of operating systems for used-car dealers — became the first Chinese company to list in the United States in 2026. It raised about $51 million at $17 a share, the midpoint of its range. The stock then fell 46.8% on its Nasdaq debut. The message was blunt: the era of large-scale Chinese listings in New York has not returned, and the deals that do get through are priced for escape velocity, not long-term holding. The drying of the U.S. channel is structural: in 2025 only 14 mainland firms received CSRC filing notices for U.S. listings, down sharply from 56 in 2024, as Nasdaq's proposed stricter thresholds for Chinese issuers moved through the approval process. As of early January, 53 mainland companies remained in the Nasdaq pipeline, waiting to see whether the new rules would let them through at all.
The broader data confirm the pattern. Of 179 listings on the Hong Kong exchange since January 2025, about half have traded lower over the past three months, according to market data. Over the same period the Hang Seng index fell only mildly, while the FTSE Renaissance Global IPO Index gained more than 10%. Chinese issuers are not merely participating in a global IPO slump — they are underperforming a market that is otherwise functioning.
The Mechanism: Why Speed Breeds Strain
The tension is structural, not cyclical. China's IPO market is being asked to serve two masters whose incentives increasingly conflict.
On one side stands the state's industrial policy. Equity financing is a core funding channel for achieving technological self-reliance, and the registration-based reform introduced in February 2023 was designed to move the market from regulator-as-gatekeeper to regulator-as-registrar. The ChiNext board reform announced by Wu Qing this year extends that logic: companies under IPO review can now sell existing shares simultaneously, and underwriters get more pricing leeway. The system is being optimized for throughput of hard-technology companies. The first half of 2026 shows the reform working as intended on the supply side: Hong Kong recorded 78 IPOs raising about HKD 203.3 billion, up 86% in number and 90% in proceeds from the same period in 2025.
On the other side stands a domestic investor base with a short memory and a long list of grievances. Chinese households are being steered toward equities as property stops absorbing savings, but they have been burned repeatedly — by the 2021–2022 tech crackdown, by the 2023–2024 IPO flood that drained liquidity, and by a CSI 300 that, at 4,592.75 on August 20, remains about 21% below the record high of 5,807.72 it set in February 2021. When supply accelerates faster than confidence returns, the secondary market punishes the marginal deal. That is the feedback loop now in motion: more listings pressure prices, weak debuts make investors more selective, and selectivity forces the next cohort of issuers to accept lower valuations — or not list at all.
The regulator knows this. The CSRC's "counter-cyclical adjustment" framework explicitly ties IPO supply to secondary-market conditions. The 2023 experience is the warning case: in that year alone, 126 companies cancelled or suspended their Shanghai Star Market applications, more than in the previous four years combined, as the market refused to absorb the pipeline. Regulators throttled supply in 2024 precisely to avoid repeating that dynamic. The 2026 acceleration tests whether the throttle can be modulated finely enough to avoid the same outcome.
There is also a valuation mismatch built into the system. A-share and H-share prices for the same company routinely trade at wide discounts — Luxshare's 13% gap was considered too narrow by Hong Kong investors because the historical norm is 20% to 30%. Issuers and their sponsors, chasing the highest possible proceeds, price for the domestic A-share premium and discover that offshore buyers will not follow. The result is a queue of companies that are approved but cannot clear the market at acceptable terms. By the end of May 2026, more than 600 active listing applications sat on Hong Kong's books, with over 100 A-share issuers among them — a backlog that represents both latent supply and latent pressure on pricing.
The concentration of the recovery makes the strain worse. In Hong Kong's first half, five mega IPOs and 12 large IPOs accounted for more than 60% of all proceeds. That leaves small and mid-cap debuts fighting over the scraps of a still-cautious liquidity pool. The pattern is not unique to China: even successful debuts struggle to hold gains. Victory Giant Technology, the printed-circuit-board maker tied to the AI chip supply chain, raised about $2.6 billion in April in Hong Kong's biggest listing of the year and jumped 50% on debut — only to give back much of that pop in the weeks that followed as the AI euphoria cooled. Success at the bell is not the same as success in the aftermarket.
The Counter-Thesis: This Is a Controlled Reopening, Not a Repeat
The strongest argument against the strain narrative is that this time the regulator holds the throttle. Unlike 2023, when listings ran ahead of market capacity, the CSRC has repeatedly demonstrated it will slow approvals when the secondary market weakens. The 2024 contraction — from 313 IPOs to 101 — is proof of concept. Supportive measures are also arriving: industry research notes that allowing long-term funds, including insurance capital, into equities could add durable demand, and AI and 15th Five-Year Plan sectors are explicitly favored by investors. "There has unquestionably been pressure on parts of China's financial sector," said Benjamin Cavender, managing director at China Market Research Group. "This has probably placed a focus on short-term performance." That focus, the counter-thesis runs, is exactly what keeps sponsors and issuers honest: with investors watching first-day performance closely, only genuinely strong names will price, and the weak ones will wait.
There is real evidence for this view. Not every debut has failed. In early January, Shanghai Biren Technology, an AI chip designer, raised more than $700 million in Hong Kong's first IPO of 2026 and finished its debut session up 76%. A day earlier, six Hong Kong listings raised about $900 million and all finished above their offer prices. Average first-day gains for Hong Kong IPOs in 2025 were about 37%, rising to 42% after a full month of trading — hardly the signature of a broken market. The counter-thesis concludes that the weak performers are the outliers, not the rule, and that the market is simply doing what it should: rewarding quality and punishing the rest.
That argument is credible but incomplete. It assumes the regulator can fine-tune supply faster than investor sentiment can sour — and it assumes that the companies now in the pipeline are genuinely different from the ones that flooded the market in 2023. The evidence cuts the other way on the second point: the same concentration in consumer electronics, the same reliance on single large customers, the same pre-revenue tech names that require rule changes to qualify. Regulatory control over the queue does not create demand for the queue's contents. Nor does it solve the offshore discount problem. And the 2025 first-day pop is a fragile foundation: a 37% average gain on debut followed by half the cohort trading lower within months is not a sign of health — it is a sign that pricing is set for the ceremony, not for the holders.
The falsifying signal is straightforward. If the next 20 to 30 A-share debuts trade at an average first-day premium above 30% and fewer than one in five Hong Kong listings break issue price over the next quarter, the strain thesis is wrong and the reopening is genuinely demand-led. If instead first-day gains compress toward zero and withdrawals climb back toward 2023 levels, the cycle is repeating.
What Comes Next
The near-term path splits into three scenarios.
In the base case, the CSRC modulates approvals to keep the pipeline moving without overwhelming the market: roughly 90 to 150 mainland listings and about RMB 150 billion in proceeds for 2026, with Hong Kong continuing to absorb mega-deals while small and mid-cap debuts struggle. Winners are hard-technology issuers with state backing and clean balance sheets; the exposed are consumer-facing companies with single-customer concentration and any issuer priced for A-share parity in offshore markets.
In the upside case, long-term fund inflows and a stabilizing property market restore investor risk appetite, allowing the market to absorb the pipeline at firm valuations. First-day premiums stay elevated, cornerstone books oversubscribe, and the 2026 cohort becomes the foundation of a multi-year issuance cycle.
In the downside case, weak debuts accelerate into a self-reinforcing spiral: investors retreat to cash, sponsors pull deals, and the CSRC is forced to re-impose the 2024-style throttle before year-end. The 126-company withdrawal wave of 2023 becomes the template rather than the cautionary tale.
Across all three scenarios, one asymmetry is clear: the regulator controls how many companies list, but it cannot control what happens after the gong sounds. China's IPO revival will be judged not by the size of the pipeline, but by the performance of the stocks already in circulation.
"The regulator made it clear on many occasions that high-quality tech companies would be welcome to go public. Therefore, the pace of IPOs is expected to speed up further in 2026." — Wang Zhengzhi, analyst at Guotai Haitong Securities
The central judgment: China's IPO market is not broken, but it is being asked to do two incompatible things at once — fund a national technology agenda and deliver returns to a skeptical investor base. The 2026 revival is a policy-driven supply shock; whether it becomes a sustainable market depends entirely on demand catching up before the next weak debut reminds everyone why the throttle was closed in the first place.
Explore more exclusive insights at nextfin.ai.
